The Delhi High Court refused Novo Nordisk interim relief against Dr Reddy’s, finding that the Semaglutide species patent faces serious validity challenges in light of the earlier genus patent. The Court allowed Dr Reddy’s to continue manufacturing Semaglutide in India solely for export to non-patent jurisdictions, with no domestic sales.
Read more about Dr Reddy’s Semaglutide Exports to Continue as Court Denies Interim Relief to Novo Nordisk